In a report released today, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $79.00. The company’s shares closed yesterday at $81.39.
Issi covers the Healthcare sector, focusing on stocks such as Bluebird Bio, Crispr Therapeutics AG, and Caribou Biosciences. According to TipRanks, Issi has an average return of -10.2% and a 39.19% success rate on recommended stocks.
In addition to RBC Capital, Crispr Therapeutics AG also received a Hold from Barclays’s Gena Wang in a report issued today. However, on the same day, JMP Securities maintained a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP).
Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $178 thousand and a GAAP net loss of $179.22 million. In comparison, last year the company earned revenue of $202 thousand and had a GAAP net loss of $113.16 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Read More on CRSP:
- Global Blood Therapeutics (GBT) was downgraded to a Hold Rating at SVB Securities
- SVB Securities Sticks to Their Buy Rating for PureTech Health (PRTC)
- Constellation Energy Corporation (CEG) Receives a Buy from Wells Fargo
- RBC Capital Sticks to Their Hold Rating for Enanta Pharmaceuticals (ENTA)
- Wells Fargo Sticks to Their Buy Rating for NextEra Energy (NEE)